Immix Biopharma (IMMX) Stock Forecast, Price Target & Predictions
IMMX Stock Forecast
Immix Biopharma stock forecast is as follows: an average price target of $7.00 (represents a 276.34% upside from IMMX’s last price of $1.86) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
IMMX Price Target
The average price target for Immix Biopharma (IMMX) is $7.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 276.34% upside from IMMX's last price of $1.86.
IMMX Analyst Ratings
According to 1 Wall Street analysts, Immix Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for IMMX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Immix Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 01, 2024 | Robert Burns | H.C. Wainwright | $7.00 | $1.98 | 253.54% | 276.34% |
The latest Immix Biopharma stock forecast, released on Jul 01, 2024 by Robert Burns from H.C. Wainwright, set a price target of $7.00, which represents a 253.54% increase from the stock price at the time of the forecast ($1.98), and a 276.34% increase from IMMX last price ($1.86).
Immix Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $7.00 | $7.00 |
| Last Closing Price | $1.86 | $1.86 | $1.86 |
| Upside/Downside | -100.00% | 276.34% | 276.34% |
In the current month, the average price target of Immix Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immix Biopharma's last price of $1.86. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 01, 2024 | H.C. Wainwright | - | Buy | Initialise |
Immix Biopharma's last stock rating was published by H.C. Wainwright on Jul 01, 2024. The company Initialise its IMMX rating from "null" to "Buy".
Immix Biopharma Financial Forecast
Immix Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Immix Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMMX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Immix Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict IMMX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immix Biopharma's previous annual EBITDA (undefined) of $NaN.
Immix Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-3.45M | $-3.74M | $-4.03M | $-3.74M | $-4.03M | $-4.61M | $-4.32M |
| High Forecast | $-3.45M | $-3.74M | $-4.03M | $-3.74M | $-4.03M | $-4.61M | $-4.32M |
| Low Forecast | $-3.45M | $-3.74M | $-4.03M | $-3.74M | $-4.03M | $-4.61M | $-4.32M |
| Surprise % | - | - | - | - | - | - | - |
Immix Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMMX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Immix Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Immix Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMMX last annual SG&A of $NaN (undefined).
Immix Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.15 |
| High Forecast | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.15 |
| Low Forecast | $-0.12 | $-0.13 | $-0.14 | $-0.13 | $-0.14 | $-0.16 | $-0.15 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Immix Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMMX previous annual EPS of $NaN (undefined).
Immix Biopharma Peer Comparison by Price Target
IMMX Forecast FAQ
Is Immix Biopharma a good buy?
Yes, according to 1 Wall Street analysts, Immix Biopharma (IMMX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of IMMX's total ratings.
What is IMMX's price target?
Immix Biopharma (IMMX) average price target is $7 with a range of $7 to $7, implying a 276.34% from its last price of $1.86. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Immix Biopharma stock go up soon?
According to Wall Street analysts' prediction for IMMX stock, the company can go up by 276.34% (from the last price of $1.86 to the average price target of $7), up by 276.34% based on the highest stock price target, and up by 276.34% based on the lowest stock price target.
Can Immix Biopharma stock reach $3?
IMMX's average twelve months analyst stock price target of $7 supports the claim that Immix Biopharma can reach $3 in the near future.
What are Immix Biopharma's analysts' financial forecasts?
Immix Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-12.953M (high $-12.953M, low $-12.953M), average SG&A $0 (high $0, low $0), and average EPS is $-0.45 (high $-0.45, low $-0.45). IMMX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-14.968M (high $-14.968M, low $-14.968M), average SG&A $0 (high $0, low $0), and average EPS is $-0.52 (high $-0.52, low $-0.52).